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Introduction {#sec005}
============

A patient web portal (PWP) can help patients increase their knowledge about the disease \[[@pone.0129403.ref001]\], improve diabetes outcomes \[[@pone.0129403.ref002]--[@pone.0129403.ref006]\], increase self-efficacy \[[@pone.0129403.ref007]\] and getting patients more involved in their own treatment \[[@pone.0129403.ref008]\]. However, adoption rates to web portals are slow. Our group and others have found differences between users and non-users of a diabetes web portal on both demographic and diabetes related variables \[[@pone.0129403.ref009],[@pone.0129403.ref010]\]. Health care providers need to focus on these differences and give extra attention to patients who could benefit from portal use. We also need to examine the way patients use a web portal and to gain insight into a patient's perspective of the usefulness of a PWP to increase its use.

Patients start using a PWP to increase their self-management \[[@pone.0129403.ref007]\], to enhance the communication with their health care provider \[[@pone.0129403.ref011]\] or because of dissatisfaction with the patient-provider relationship \[[@pone.0129403.ref012]\]. There are barriers that prevent patients from starting or continuing the use of a web portal, such as fear for privacy \[[@pone.0129403.ref013]\], non-feedback frustration and difficulty implementing PWP use in daily life \[[@pone.0129403.ref014]\]. Some patients may have incorrect assumptions about a PWP leading to expectations that are not met \[[@pone.0129403.ref015]\]. Furthermore, patients have specific wishes for content and additional personalized online services to improve portals \[[@pone.0129403.ref013]\].

Because many portals have been designed by physicians and IT-specialists, and not by patients themselves, redesign of the web portals might be needed to interest as many patients as possible and to address their specific wishes and needs. We aimed to gain insight into the experiences, motivations and preferences of persistent users and early quitters of a diabetes PWP.

The following research questions were addressed: 1. What are the characteristics of patients who request a login and become a persistent user in comparison to patients who cease to use the portal in an early stage? 2. Why do patients request a login to the web portal? 3. How is the web portal being used? 4. How do patients assess the content of the web portal? 5. What are the patients' wishes for improvement?

Materials and Methods {#sec006}
=====================

Study setting and design {#sec007}
------------------------

All participants had to sign a consent form to participate. In the Netherlands, studies involving human subjects need to undergo a medical ethics review if they are subjected to the Medical Research Involving Human Subject Act (WMO). This study was assessed and considered non-WMO applicable by the Medical Ethics Committee of the University of Utrecht, which means that no further ethical approval was required (protocol number 11-296/C).

'Diamuraal' is an organization that coordinates the diabetes care in a defined geographical area in the center of the Netherlands. It comprises 62 independent primary care practices and one outpatient clinic of the regional hospital that provide diabetes care to over 10.000 patients, working in a care group \[[@pone.0129403.ref016],[@pone.0129403.ref017]\]. All physicians and nurses who participate in the care of these patients record their data in the same electronic health record and patients can request a log-in to access their personal medical records. This portal is called 'Digitaal Logboek' and was developed by Diamuraal and a private company (Portavita). After login, patients have access to the information provided by their physician or nurse during medical consultations. These include full-text of the clinic notes, the results of physical examination, laboratory results, problem lists and treatment goals. Patients can view a list of their current use of medications, however the completeness of this list is depending on the physician because this needs to be manually added. The PWP also provides general diabetes information and an overview of all examinations and visits that are needed in high quality diabetes care. Patients can upload glucose levels measured at home ([Fig 1](#pone.0129403.g001){ref-type="fig"}) and contact their personal care provider through secured e-messaging. This portal is an integral part of the EMR, all interactions and messages between patient and provider are stored in the EMR. The portal is additional; patients who have not requested access receive usual diabetes care. We conducted a survey among adult patients with type 1 or 2 diabetes mellitus. The physicians working within the organization of 'Diamuraal' have registered their patients with this organization and all data about patient characteristics and data concerning the disease are recorded in the electronic health record, including if a patient has requested a login to the web portal. For this survey we randomly selected 1500 patients aged 18--85 years with a login to the web portal. As part of our study, we also sent different questionnaires to patients within 'Diamuraal' that are registered as not having a login (non-users). Information about the latter group of patients has been published elsewhere and is beyond the scope of this paper \[[@pone.0129403.ref018]\]. Patients were sent an informational letter together with a questionnaire. They received a reminder twice in a three week interval. All participants had to sign a consent form to participate. In the Netherlands, studies involving human subjects need to undergo a medical ethics review if they are subjected to the Medical Research Involving Human Subject Act (WMO). This study was assessed and considered non-WMO applicable by the Medical Ethics Committee of the University of Utrecht, which means that no further ethical approval was required (protocol number 11-296/C).

![Screenshot of the glucose diary of the patient portal.](pone.0129403.g001){#pone.0129403.g001}

Study measures {#sec008}
--------------

We collected patient data form the electronic health record, such as login frequency, age, gender, type of diabetes, treatment setting, laboratory values, comorbidity and diabetic complications.

The questionnaire about the portal contained multiple choice questions about reasons for requesting a login, the usability of portal features and patient's wishes. For all questions, see [S1 Questionnaire](#pone.0129403.s001){ref-type="supplementary-material"}. There were three questions that were scored on a 5-point Likert scale. We combined the two highest categories (very useful and useful; very satisfied and satisfied; very important and important) in the analysis.

We used an additional small questionnaire for asking educational level, ethnicity, living status, employment, medication, current smoking, drinking alcohol, physical activity, access to internet and to a computer. Finally we added several validated questionnaires to measure: satisfaction with diabetes treatment (The Diabetes Treatment Satisfaction Questionnaire, DTSQ) \[[@pone.0129403.ref019]\]; diabetes-specific distress (Problem Areas in Diabetes, PAID) \[[@pone.0129403.ref020],[@pone.0129403.ref021]\]; self-efficacy (Diabetes Management Self-Efficacy Scale, DMSES) \[[@pone.0129403.ref022]\] and diabetes knowledge (Brief Diabetes Knowledge Test, BDKT) \[[@pone.0129403.ref023],[@pone.0129403.ref024]\]. These measures are described in more detail elsewhere \[[@pone.0129403.ref009]\]. Data is deposited in Dryad \[[@pone.0129403.ref025]\].

Statistical analysis {#sec009}
--------------------

The patients were analyzed according to their login-frequency. We compared two groups: patients who requested a login but never used it or only once ('early quitters') and patients who requested a login and used it at least two times ('persistent users'). This division is based on registered data on the number of actual logins in the patient web portal from the first access to the portal. The period of access may range from about three years to just a few months. Our definition of persistent users and early quitters is comparable to data other studies (\[[@pone.0129403.ref026],[@pone.0129403.ref027]\]).

Categorical variables were expressed as percentages and continuous variables as means with standard deviation (SD). We used χ2-tests for all categorical variables and unpaired t-tests for all continuous variables. Logistic regression was used to determine which variables are independently associated with the cessation or continuation of the portal. We used a p-value of \<0.2 in the univariable analysis to select variables for multivariable analysis. The reasons for use, the answers about content and usefulness of the portal and about the wishes were expressed as percentages. The answer categories 'useful' and 'very useful' were combined.

Data was analyzed using SPSS for Windows (versions 20, SPSS Inc., Chicago, IL, USA).

Results {#sec010}
=======

From 1500 questionnaires 24 were undeliverable. Of the 1476 patients who received a questionnaire, 632 (42.8%) patients returned a completed questionnaire and were eligible for analysis (responders). Their mean age was 59.7 ± 13.2 years (versus non-responders 56.8 ± 15.1, p\<0.001) and 63.1% was male (versus non-responders 57.1%, p = 0.02). 413 (65.3%) patients were 'persistent users' (PU) and 219 (34.7%) patients were 'early quitters' (EQ).

Characteristics of early quitters versus persistent users {#sec011}
---------------------------------------------------------

Persistent users were younger and had more often a paid job. More of them used insulin, were treated by an internist and used the internet daily. They had better diabetes knowledge and experienced both more hypoglycemic and hyperglycemic episodes ([Table 1](#pone.0129403.t001){ref-type="table"}). The use of insulin, more frequently perceived hyperglycemic episodes and better diabetes knowledge increased the odds of becoming a persistent user. With a higher HbA1c the odds of becoming a persistent users decreases ([Table 2](#pone.0129403.t002){ref-type="table"}). When using the internet, responders from both groups were mostly over an hour online (PU 45.4% versus EQ 36.0%, p = 0.18). Furthermore, 51.1% of the persistent users declared that they used the internet for searching information about their disease compared with only 22.0% of the early quitters (p\<0.001).

10.1371/journal.pone.0129403.t001

###### Characteristics of the study participants (n = 632), mean ± SD or %.

![](pone.0129403.t001){#pone.0129403.t001g}

                                                                             Early quitters (n = 219)   Persistent users (n = 413)   P-value
  --------------------------------------------------- ---------------------- -------------------------- ---------------------------- ----------
  Age, years                                                                 61.9 ± 12.7                58.5 ± 13.3                  0.02
  Gender, male                                                               63.9                       62.7                         0.76
  Caucasian                                                                  91.2                       93.6                         0.26
  Educational level, high                                                    39.4                       46.2                         0.11
  Paid job                                                                   36.3                       47.1                         0.01
  Living arrangement, alone                                                  16.8                       15.9                         0.76
  Fluency in speaking Dutch                                                  97.2                       99.3                         0.07
  Daily use of internet                                                      63.0                       77.9                         \<0.001
  Treatment setting                                   General practitioner   54.8                       43.6                         0.01
  Internist                                           45.2                   56.4                                                    
  Type of Diabetes                                    Type 1                 15.5                       19.6                         0.21
  Type 2                                              84.5                   80.4                                                    
  Duration of Diabetes, years                                                13.9 ± 11.0                13.3 ± 10.7                  0.49
  Insulin                                                                    45.9                       63.2                         \< 0.001
  Polypharmacy[\*](#t001fn001){ref-type="table-fn"}                          47.2                       52.7                         0.21
  HbA1c (mmol/mol)                                                           54.0 ± 12.0                55.5 ± 11.2                  0.14
  Total cholesterol (mmol)                                                   4.3 ± 1.0                  4.4 ± 1.0                    0.46
  Current smoker                                                             16.4                       11.5                         0.09
  Drinking alcohol                                                           49.3                       52.8                         0.41
  PAID (range 0--100)                                                        29.3 ± 11.5                31.0 ± 11.8                  0.11
  DMSES (range 20--100)                                                      80.7 ± 16.5                80.7 ± 15.5                  0.97
  BDKT standard (range 0--100)                                               70.6 ± 18.8                78.7 ± 14.7                  \< 0.001
  BDKT insulin (range 0--100)                                                58.0 ± 19.2                61.4 ± 20.6                  0.15
  DTSQ status (range 0--36)                                                  29.8 ± 5.3                 30.2 ± 5.0                   0.37
  DTSQ hyper (range 0--6)                                                    2.0 ± 1.8                  2.7 ± 1.9                    \< 0.001
  DTSQ hypo (range 0--6)                                                     1.6 ± 1.6                  2.0 ± 1.7                    0.01

\* polypharmacy: the use of five or more medications.

10.1371/journal.pone.0129403.t002

###### Independent determinants of becoming regular users compared to early quitters.
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                  OR (95% CI)         P-value
  --------------- ------------------- ---------
  Insulin         2.07 (1.18--3.62)   0.01
  HbA1c           0.97 (0.95--0.99)   \< 0.01
  BDKT standard   1.02 (1.01--1.03)   \< 0.01
  DTSQ hyper      1.30 (1.14--1.49)   \<0.001

Reasons for requesting a login {#sec012}
------------------------------

The majority of patients from both groups declared that they 'discovered' the existence of the PWP after being informed by their physician (PU 94.9%, EQ 77.6%, p\<0.001). For persistent users, the main two reasons for requesting a login were that the portal could give them access to the laboratory results and treatment goals (75.5%) and that the portal could influence disease and management (42.5%). For early quitters, the two main reasons for requesting a login were the access to the clinic notes and laboratory results (42.9%) and the suggested use of the portal by others (20.5%).

The general usefulness and usefulness of specific content {#sec013}
---------------------------------------------------------

The majority of the persistent users (53.1%) accessed the web portal less than once a month and half of them spent less than fifteen minutes per session. They declared it easy to use (PU 91.9% versus EQ 78.7%, p\<0.001); easy to login (PU 96.8% versus EQ 86.0%, p\<0.001); they were satisfied with the layout (PU 96.8% versus EQ 85.2%, p\<0.001) and assessed the overall information to be comprehensible (PU 97.5% versus EQ 90.4%, p = 0.01). The same held true for the comprehensibility of specific web portal items: the meaning of laboratory values (PU 92.0% versus EQ 77.1%, p\<0.001), the abbreviations used (PU 75.8% versus EQ 54.9%, p\<0.001), the medical phrasings (PU 69.4% versus EQ 49.0%), p\<0.001) and the reasons of why the appointments and check-ups in the clinic are needed (PU 91.7% versus EQ 73.0%, p\<0.001). The majority of both persistent users (77.0%) and early quitters (79.3%) declared that they never had contacted the helpdesk for support (p = 0.66). Of the people who did contact the helpdesk the main reason in both groups was because of losing their passwords (PU 49.5% versus EQ 64.7%, p = 0.28).

Both persistent users and early quitters appreciated most that they could reread at their homes the information discussed during consultations, the access to their laboratory values and treatment goals; persistent users rated the usefulness of all these items significantly higher than early quitters ([Table 3](#pone.0129403.t003){ref-type="table"}).

10.1371/journal.pone.0129403.t003

###### Early quitters and persistent users regarding the perceived usefulness (very useful or useful) of the content items of the patient web portal.
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                                              Early quitters (n = 219)   Persistent users (n = 413)   P-value          
  ------------------------------------------- -------------------------- ---------------------------- --------- ------ ----------
  Summary of upcoming visits                  147                        65.3                         401       78.8   \< 0.01
  Summary of all physicians / caregivers      144                        52.8                         396       61.4   0.18
  e-messaging                                 144                        56.2                         401       74.6   \< 0.001
  General diabetes information                144                        42.4                         396       53.8   0.06
  Glucose diary                               144                        47.2                         401       72.1   \< 0.001
  Rereading clinic visit                      146                        72.6                         402       89.6   \< 0.001
  Laboratory values + treatment goals         147                        72.1                         403       92.3   \< 0.001
  Summary of all controls (past and future)   146                        67.8                         402       84.1   \<0.001
  Summary of medication                       144                        62.5                         401       64.6   0.90

\* number of patients who answered that question.

More PU than EQ stated that they know their own HbA1c and cholesterol levels and the targets for weight, HbA1c and blood pressure. When asked if the portal helps with supporting life style changes, about half of PU scored items negatively. The EQ felt significantly more items not applicable in their situation compared to PU ([Table 4](#pone.0129403.t004){ref-type="table"}).

10.1371/journal.pone.0129403.t004

###### Opinions of early quitters (n = 219) versus persistent users (n = 413) about the way the portal being supportive for care.
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  Survey question                                    Early quitters   Persistent users   P-value                                     
  -------------------------------------------------- ---------------- ------------------ --------- ------ ----- ------ ------ ------ ---------
  **Do you know...?**                                                                                                                
  ...the value of your own weight?                   189              100                                 409   99.3                 0.24
  ...the value of your blood pressure?               184              94.6                                407   93.1                 0.68
  ...the value of your Hba1c?                        184              60.3                                402   82.1                 \<0.001
  ... the value of your cholesterol?                 184              70.7                                408   85.3                 \<0.001
  ...the treatment goals of your weight?             183              88.0                                407   92.9                 0.05
  ...the treatment goals of your blood pressure?     183              84.6                                407   91.9                 \<0.01
  ...the treatment goals of your HbA1c?              179              62.0                                402   82.6                 \<0.001
  ...the treatment goals of your weight?             178              96.1                                404   83.7                 \<0.001
  **Do you believe the portal will help with...?**                                                                                   
  ...adherence to diet                               165              14.5               56.4      29.1   405   15.6   66.7   17.8   0.01
  ...adherence to sport                              166              10.2               56.0      33.7   402   11.4   66.7   21.9   0.01
  ...losing weight                                   167              17.4               53.9      28.7   401   17.5   60.3   22.2   0.23
  ...stop smoking                                    168              4.2                40.5      55.4   401   3.7    37.4   58.9   0.83
  ...adherence in taking medication                  166              15.7               51.2      33.1   393   21.4   64.1   14.5   \<0.001
  ...diabetes knowledge                              166              34.9               39.2      25.9   401   49.4   43.4   7.5    \<0.001
  ...preventing complications                        167              21.6               49.1      29.3   403   32.8   55.8   11.4   \<0.001

\* number of patients who gave an answer to that question.

Wishes for improvement {#sec014}
----------------------

Persistent users and early quitters answer differently about additional items which could improve the web portal ([Table 5](#pone.0129403.t005){ref-type="table"}). PU want to be able to add their injected insulin units to the glucose diary, to receive updates with current medical information about diabetes and to use the portal for supporting the diabetes care, like scheduling a clinic visit. Among EQ the desires concerning reminder functions for upcoming visits, information about medication and side-effects and automatic upload from glucose meters are most often listed. It should be noted that the majority of PU also wish to have these functionalities added to the PWP.

10.1371/journal.pone.0129403.t005

###### Wishes about additional functionalities.
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                                                             Early quitters (n = 219)   Persistent users (n = 413)   P-value                
  ---------------------------------------------------------- -------------------------- ---------------------------- --------- ------------ ----------
  Automatic signal to physician by uploading glucose diary   164                        74 (45.1)                    402       197 (49.0)   0.48
  Automatic upload from glucose meter to portal              162                        85 (52.5)                    399       231 (57.9)   0.49
  Adding insulin units to glucose diary                      118                        60 (50.8)                    297       199 (67.0)   \< 0.001
  Links to websites with information about diabetes          170                        43 (25.3)                    397       167 (42.1)   \< 0.01
  Links to websites with interventions                       167                        40 (24.0)                    394       111 (28.2)   0.58
  Portal on mobile device                                    166                        21 (12.7)                    393       78 (19.8)    0.10
  Request for medication refills                             168                        84 (50.0)                    396       231 (58.3)   0.11
  Forum                                                      165                        25 (15.2)                    396       70 (17.7)    0.69
  Printing functionality                                     163                        70 (42.9)                    396       197 (49.7)   0.23
  Updates with current medical information about diabetes    167                        86 (51.5)                    395       245 (61.7)   0.01
  Information in different languages                         166                        18 (10.1)                    393       31 (7.9)     0.26
  Information about medication and side effects              169                        95 (56.2)                    401       238 (59.4)   0.75
  Reminder function when scheduled / upcoming visit is due   170                        100 (58.8)                   404       282 (69.8)   0.04
  Using the portal for scheduling a visit with physician     170                        73 (42.9)                    403       263 (65.3)   \< 0.001

\* number of patients who answered that question.

Discussion {#sec015}
==========

This study provides insight into the experiences, motivations and preferences of persistent users and early quitters of a diabetes web portal. With this information we can adjust the portal to the potential users' wishes and preferences.

The main reason all patients requested access to the patient web portal was because it could give them access to laboratory results and treatment goals. Apparently patients are interested in using a PWP as a tool in managing their disease. Most patients 'discovered' the existence of the PWP after being informed by their care provider. Among the EQ there was a large group that got interested in the PWP by other means like posters in waiting areas or pamphlets. We assume that most of the latter group did not discuss the PWP with their treating physician. This implies that there is an important role for the health care provider in turning the patient into a PU. Modelling expectations can prevent early quitting due to disappointment \[[@pone.0129403.ref015]\]. Referral to the PWP during consultations may prompt patients to return to their PWP.

Patients who became persistent users were apparently those with a higher disease seriousness. Also among parents with children with a chronic disease, low level of disease severity was one of the reasons for not using the portal \[[@pone.0129403.ref028]\]. However, a recent systematic review on the use of electronic portal usage among patients with diabetes showed mixed outcomes in this respect \[[@pone.0129403.ref029]\]. We may conclude that one uniform portal is not suitable for all patients and we should consider dividing a diabetes web portal immediately after the entrance in two parts: one for patients who are injecting insulin and another for patients who do not. In patients with type 2 diabetes from the same organization, we previously found insulin use is a predictor of requesting a login \[[@pone.0129403.ref009]\]. Designing different portals will meet the needs of different categories of patients and could also meet the preferences of early quitters to get more information about (oral) medication and its side-effects.

Even two thirds of the persistent users responded that they did not feel the portal supports them in most lifestyle choices. We do not know the reason for this, but it might be because in the current portal most of these items are incorporated in other parts of the portal, like in the free text box at the end of the consult summary. In redesigning the portal, this finding has to be taken into account. A second explanation could be, that most of the users have both a low frequency and a low duration of accessing the portal, as in other studies \[[@pone.0129403.ref028],[@pone.0129403.ref030]\]. This low frequency could explain why patients consider it not supportive in incorporating its information about life-style changes in daily life \[[@pone.0129403.ref014]\]. We could help reminding the patients using the PWP by a simple adjustment in portal functionality, e.g. an automatically generated email to remind patients to log in and evaluate their lifestyle and the agreement they made about it with their physician. If necessary they can use the e-messaging for questions and support when encountering difficulties in the implementation. In other types of web portals, weight and activity logs are implemented to encourage life style changes \[[@pone.0129403.ref011]\].

Persistent users perceived the comprehensibility of the portal more favorable than early quitters. One of the reasons of early quitting might be the medical language. Indeed, medical terms and abbreviations require explanation \[[@pone.0129403.ref013],[@pone.0129403.ref031]\]. Besides the already available online manual we could offer a course or workshop on navigating through and understanding the portal. The ideas we offer in this paper for improvement of the patient web portal are against the background that the PWP we studied is a static coded website. Other portals might use technology that allows a more dynamic approach, in which sections appear based on patient characteristics. For new portals that are still in a design phase, this should be taken into consideration.

Study strengths include a large and representative population with both type 1 and type 2 diabetes patients and patients from primary as well as secondary care. The diabetes portal in this study is already 6 years in use, which adds to the value of patients' opinions. Furthermore, besides the survey data about users' opinions we used actual data about number of logins and patient characteristics, derived from the central 'Diamuraal' database, that encompasses all patients with diabetes mellitus treated by primary care physicians and internists who participate in 'Diamuraal'.

Nevertheless, there are limitations: only 42.8% of the approached people responded. This percentage is comparable with a previously found willingness of diabetes patients in participating in research \[[@pone.0129403.ref032]\]. Our participants were slightly older and more frequently male. However, both age and gender were not a determinant for becoming a persistent user; therefore the selective participation may not have influenced the outcomes. It is unclear if we can generalize our results to the entire diabetes population in the Netherlands because there is no national diabetes registry. However, irrespective of the representativeness of our study population, issues raised in this paper about problems with comprehensibility of the portal, supporting lifestyle changes and additional wishes for portal features should be taken into account when designing a patient portal for patients with diabetes. Another limitation is the cut-off point of 2 times login for the definition 'persistent user' or 'early quitter'. To the best of our knowledge there is no definition of how many login times makes a person a persistent user. For that reason we had to make a judgment call based on the distribution of actual logins from the first access to the portal. This paper does not include information about the group of patients that never requested a login (the so called 'non-users'). They are not able to provide information about the use of the portal the scope of this paper. Compared to users, the non-users are older (59.7±13.2 years vs. 67.4±10.0 years, P\<0.001) and less frequently male (63.1% vs. 56.6%).

In conclusion, medical terms and abbreviations in a PWP require explanation. Patients who are prescribed insulin, perceive hypoglycemic episodes and have better diabetes knowledge are the ones who become persistent users of a PWP. Persistent users evaluate the portal more favorable and would like to be able to add their injected insulin units to the glucose diary. We consider dividing a diabetes web portal immediately after the entrance in two parts: one for patients who are injecting insulin and another for patients who do not. This suggestion also meets the preferences of early quitters to get more information about (oral) medication and its side-effects.
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